Distinct roles of cell wall biogenesis in yeast morphogenesis as revealed by multivariate analysis of high-dimensional morphometric data

Hiroki Okada, Shinsuke Ohnuki, Cesar Roncero, James B. Konopka, and Yoshikazu Ohyaa

INTRODUCTION

The fungal cell wall is a rigid structure that plays important roles in the establishment and maintenance of cell shape (Klis et al., 2006). Without the cell wall, fungal cells could not form their unique morphology. Cells of the budding yeast Saccharomyces cerevisiae have

ABSTRACT The cell wall of budding yeast is a rigid structure composed of multiple components. To thoroughly understand its involvement in morphogenesis, we used the image analysis software CalMorph to quantitatively analyze cell morphology after treatment with drugs that inhibit different processes during cell wall synthesis. Cells treated with cell wall–affecting drugs exhibited broader necks and increased morphological variation. Tunicamycin, which inhibits the initial step of N-glycosylation of cell wall mannoproteins, induced morphologies similar to those of strains defective in α-mannosylation. The chitin synthase inhibitor nikkomycin Z induced morphological changes similar to those of mutants defective in chitin transglycosylase, possibly due to the critical role of chitin in anchoring the β-glucan network. To define the mode of action of echinocandin B, a 1,3-β-glucan synthase inhibitor, we compared the morphology it induced with mutants of Fks1 that contains the catalytic domain for 1,3-β-glucan synthesis. Echinocandin B exerted morphological effects similar to those observed in some fks1 mutants, with defects in cell polarity and reduced glucan synthesis activity, suggesting that echinocandin B affects not only 1,3-β-glucan synthesis, but also another functional domain. Thus our multivariate analyses reveal discrete functions of cell wall components and increase our understanding of the pharmacology of antifungal drugs.
major nonfilamentous cell wall components are mannoproteins, which are mannose-containing glycoproteins. These heavily glycosylated proteins are typically found on the exterior of the cell wall. Most mannoproteins are glycosylphosphatidylinositol-anchored proteins and are connected to 1,6-β-glucan chains. Thus, covalent linkages between the various components of the cell wall give rise to its elastic and plastic properties, providing a strong, continuous fabric.

The fact that the different types of yeast cell wall components are interconnected suggests that the disruption of individual cell wall biosynthetic pathways would result in similar morphological phenotypes. Alternatively, the contribution of different components to cell morphology may differ because the physical strength and flexibility of the filamentous and nonfilamentous components vary. Several studies examined the effects of perturbing the synthesis or the cross-linking of cell wall components (de Groot et al., 2001; Nishiyama et al., 2002; Schmidt et al., 2003, 2005; Blanco et al., 2012). However, qualitative observation by eye has limited power to resolve the morphological differences caused by the mutation of genes encoding the enzymes involved in cell wall synthesis. To date, no quantitative morphological analyses of cell wall mutant strains have been performed.

To examine yeast cell morphology quantitatively, we developed an automated image processing system called CalMorph (Ohtani et al., 2004). This system is a high-throughput, high-resolution image processing software package that enables the quantification of 501 cell morphology parameters from fluorescence images of the cell wall, actin, and nuclear DNA of yeast cells (Ohya et al., 2005). On the basis of a morphological analysis of the 4718 haploid nongenetic gene deletion mutants, we created a morphological database named the Saccharomyces cerevisiae Morphological Database (SCMD; http://yeast.gi.k.u-tokyo.ac.jp; Saito et al., 2004). Analysis of the data for this large set of mutants revealed significant new relationships between morphological phenotypes and gene functions (Ohya et al., 2005). Further detailed phenotypic analysis of clusters of mutants with similar phenotypes revealed new insights into complex cellular pathways (Ohnuki et al., 2007; Okada et al., 2010; Yoshida et al., 2013). In addition, we were able to predict the intracellular targets of specific drugs by comparing their morphological effects to the database (Ohnuki et al., 2010; Iwaki et al., 2013).

To gain further insight into the involvement of the cell wall in morphogenesis, we quantitatively analyzed the morphological changes induced by echinocandin B (EB), tunicamycin (TM), and nikkomycin Z (NZ), drugs that block cell wall biosynthesis pathways. Specifically, EB is a noncompetitive inhibitor of 1,3-β-glucan synthase (GS; Sawistowska-Schröder et al., 1991). Multivariate analyses of the morphological changes induced by these drugs, as well as a comparison of the cell wall mutants, revealed discrete functions of the cell wall components in determining cell morphology.

RESULTS
Morphological effects of cell wall–affecting drugs
The morphological effects of treating haploid yeast with drugs that perturb the cell wall (EB, TM, and NZ) were examined by using fluorescence microscopy to observe the cell wall, actin, and nuclear DNA. Visual inspection revealed that cells treated with 4 μg/ml EB, 100 ng/ml TM, and 400 μM NZ exhibited abnormal morphologies (Figure 1A). To explore the dose-dependent changes, we quantified 501 morphometric parameters using CalMorph (Ohtani et al., 2004) after treatment with various concentrations of the drugs and performed a principal component analysis (PCA). PCA is an exploratory multivariate statistical technique for simplifying complex data sets, and it has been used for analyzing the effects of dose-dependent changes on morphology (Ohnuki et al., 2012). Figure 1B shows that the first principal component (PC1) scores increased in a dose-dependent manner for each of the cell wall–affecting drugs, suggesting that similar morphological changes were progressively more apparent in the data sets. Next we performed a second PCA to identify dose-dependent parameters that are independent of each other (see Materials and Methods). Accordingly, we identified seven, eight, and two representative parameters for EB, TM, and NZ, respectively (Supplemental Figures S1 and S2 and Supplemental Tables S1, a–c, and S2, a–c).

Figure 2 illustrates the morphological changes induced by EB, TM, and NZ, in which all representative parameters significantly affected by the drugs are shown (p < 0.0001 after Bonferroni correction using the t test), as well as the progression of the cell cycle stages, including unbudded cells (G1), budded cells with a single nucleus (S/G2), and budded cells with two nuclei (M). Of note, treatment with all three drugs resulted in an increased neck width (red). Neck width increased at 0.1–0.3 μm with the EB, TM, and NZ treatments (Figures 1A and 3), suggesting that preservation of the neck structure is a major role of the yeast cell wall. In addition to the unique features for each cell wall–affecting drug (black), we identified features common to EB and TM (green), EB and NZ (blue), and TM and NZ (brown). The morphological features induced by TM overlapped with those induced by EB. As reported previously, the proportion of small budded cells increased after EB treatment (Digonová et al., 1999). Cells were enlarged after TM treatment, as described previously (Arnold and Tanner, 1982). In addition to the known cell morphological changes, we found that actin and the nucleus were also affected. The nuclear size increased after EB and TM treatment, and actin was delocalized in EB- and NZ-treated cells. These quantitative analyses revealed that each cell wall component had different and distinct functions in cell, actin, and nuclear morphology.

Phenotypic variation after treatment with cell wall–affecting drugs
To investigate phenotypic variations, we compared the distribution of variance with and without cell wall drugs. Among the parameters with notable drug effects (Jonckheere–Terpstra test, p < 0.05), the variance was greater in EB-, TM-, and NZ-treated cells (Figure 4, A, D, and G). We found that 65% (128/197), 54% (69/127), and 84% (31/37) of the parameters showed a broad distribution after treatment with EB, TM, and NZ, respectively. Mother cell size (parameter C11-1_A) exhibited marked variance among the five replicates after the EB treatment (Figure 4B). Similarly, the long axis in bud (parameter C107_C) and mother cell fitness for ellipse (parameter C13_C) exhibited greater variance after the TM and NZ treatments, respectively (Figure 4, E and H). Phenotypic variation in each trait can be partitioned into the contribution of variations among the cell population and measurement errors. Significantly greater variations among the cell populations were detected after drug treatments (Figure 4, C, F, and I; p < 0.05 after Bonferroni correction, Mann–Whitney U test), which suggested that phenotypic variation could be explained in part by variation in the cell population.

Effects of EB, TM, and NZ on cell morphology
To compare the effects of the cell wall–affecting drugs, we plotted dose-dependent morphological changes in a two-dimensional (2D)
space of “similarity” and “dissimilarity.” Similar parameters were defined as those with the same direction of changes after treatment with the two drugs, whereas dissimilar parameters exhibited changes in the opposite direction (see Materials and Methods). As shown in Figure 5A, similar and dissimilar parameters were located in the first/third quadrants and second/fourth quadrants, respectively. Representative similar and dissimilar features were then extracted by reducing the dimensions by PCA (Figure 5B and Supplemental Figure S3).

The EB and TM treatments are compared in Figure 5C. The EB treatment decreased from the point of origin, but the TM treatment increased with increasing concentrations, separating the effects of the two drugs. Treatment with mafungin, another GS inhibitor, also decreased, similar to EB. Given that mafungin had similar effects to EB, drugs with the same activity showed similar behavior in the similar/dissimilar 2D space.

We also compared EB and NZ treatments and TM and NZ treatments (Supplemental Figure S4). Supplemental Figure S4A shows that EB, NZ, and TM behaved differently but that mafungin acted similarly to EB. TM, NZ, and EB also worked differently in the similar/dissimilar 2D space (Supplemental Figure S4B). Therefore EB, TM, and NZ had distinct effects on cell morphology, as expected from their rather different cellular effects.

Nonessential deletion mutants with morphologies similar to those induced by drug treatments

To validate the analytical system, we compared the morphological profile of cells treated with the cell wall–affecting drugs to those of the nonessential deletion mutants with defects in cell wall–related genes (Lesage and Bussey, 2006; Orlean, 2012). The deletion mutants of the cell wall targets should have similar morphological profiles as cells treated with the cell wall–affecting drugs.

The morphological profiles induced by the TM treatment showed significant similarities to those induced by individual deletions of five genes (MNN10, ANP1, OCH1, MNN2, and HOC1) that encode mannosyltransferase in the Golgi (Figure 6; \( p < 0.05 \) after Bonferroni correction, t test). The correlation coefficient for mnn10 was 0.59.

TM-treated cells were also similar to mutants of cax4, a dolichyl pyrophosphate phosphatase that supplies dolichol-linked oligosaccharide substrates for \( \text{N-} \)glycosylation in the endoplasmic reticulum (ER; van Berkel et al., 1999). The Gene Ontology term analysis with the significantly similar 85 gene deletion mutants (\( p < 0.0001 \) after Bonferroni correction, t test) showed enrichment of \( \alpha-1,6-\)mannosyltransferase activity (Supplemental Table S4). These results are consistent with the mode of action of TM, which blocks \( \text{N-} \)glycosylation (Ballou, 1990; Jigami, 2008).

Of the three chitin synthase mutants, only the chs1 and chs3 mutants were viable and therefore testable in our assay. Neither of these mutants was morphologically similar to NZ-treated cells, probably because NZ targets more than one chitin synthase in vivo. NZ-treated cells were morphologically similar to the utr2 (crh2) mutant (Figure 6; \( r = 0.42 \)), which was defective for the major chitin transglycosylase that functions in the transfer of chitin to 1,3-\( \beta- \) and 1,6-\( \beta- \)glucans (Cabib et al., 2007). In contrast, the morphologies of the crh1 mutant (defective in minor chitin transglycosylase) and the crtt mutant (defective in cross-linking during

Nonessential deletion mutants with morphologies similar to those induced by drug treatments

To validate the analytical system, we compared the morphological profile of cells treated with the cell wall–affecting drugs to those of the nonessential deletion mutants with defects in cell wall–related genes (Lesage and Bussey, 2006; Orlean, 2012). The deletion mutants of the cell wall targets should have similar morphological profiles as cells treated with the cell wall–affecting drugs.

The morphological profiles induced by the TM treatment showed significant similarities to those induced by individual deletions of five genes (MNN10, ANP1, OCH1, MNN2, and HOC1) that encode mannosyltransferase in the Golgi (Figure 6; \( p < 0.05 \) after Bonferroni correction, t test). The correlation coefficient for mnn10 was 0.59.

TM-treated cells were also similar to mutants of cax4, a dolichyl pyrophosphate phosphatase that supplies dolichol-linked oligosaccharide substrates for \( \text{N-} \)glycosylation in the endoplasmic reticulum (ER; van Berkel et al., 1999). The Gene Ontology term analysis with the significantly similar 85 gene deletion mutants (\( p < 0.0001 \) after Bonferroni correction, t test) showed enrichment of \( \alpha-1,6-\)mannosyltransferase activity (Supplemental Table S4). These results are consistent with the mode of action of TM, which blocks \( \text{N-} \)glycosylation (Ballou, 1990; Jigami, 2008).

Of the three chitin synthase mutants, only the chs1 and chs3 mutants were viable and therefore testable in our assay. Neither of these mutants was morphologically similar to NZ-treated cells, probably because NZ targets more than one chitin synthase in vivo. NZ-treated cells were morphologically similar to the utr2 (crh2) mutant (Figure 6; \( r = 0.42 \)), which was defective for the major chitin transglycosylase that functions in the transfer of chitin to 1,3-\( \beta- \) and 1,6-\( \beta- \)glucans (Cabib et al., 2007). In contrast, the morphologies of the crh1 mutant (defective in minor chitin transglycosylase) and the crtt mutant (defective in cross-linking during

Nonessential deletion mutants with morphologies similar to those induced by drug treatments

To validate the analytical system, we compared the morphological profile of cells treated with the cell wall–affecting drugs to those of the nonessential deletion mutants with defects in cell wall–related genes (Lesage and Bussey, 2006; Orlean, 2012). The deletion mutants of the cell wall targets should have similar morphological profiles as cells treated with the cell wall–affecting drugs.

The morphological profiles induced by the TM treatment showed significant similarities to those induced by individual deletions of five genes (MNN10, ANP1, OCH1, MNN2, and HOC1) that encode mannosyltransferase in the Golgi (Figure 6; \( p < 0.05 \) after Bonferroni correction, t test). The correlation coefficient for mnn10 was 0.59.

TM-treated cells were also similar to mutants of cax4, a dolichyl pyrophosphate phosphatase that supplies dolichol-linked oligosaccharide substrates for \( \text{N-} \)glycosylation in the endoplasmic reticulum (ER; van Berkel et al., 1999). The Gene Ontology term analysis with the significantly similar 85 gene deletion mutants (\( p < 0.0001 \) after Bonferroni correction, t test) showed enrichment of \( \alpha-1,6-\)mannosyltransferase activity (Supplemental Table S4). These results are consistent with the mode of action of TM, which blocks \( \text{N-} \)glycosylation (Ballou, 1990; Jigami, 2008).

Of the three chitin synthase mutants, only the chs1 and chs3 mutants were viable and therefore testable in our assay. Neither of these mutants was morphologically similar to NZ-treated cells, probably because NZ targets more than one chitin synthase in vivo. NZ-treated cells were morphologically similar to the utr2 (crh2) mutant (Figure 6; \( r = 0.42 \)), which was defective for the major chitin transglycosylase that functions in the transfer of chitin to 1,3-\( \beta- \) and 1,6-\( \beta- \)glucans (Cabib et al., 2007). In contrast, the morphologies of the crh1 mutant (defective in minor chitin transglycosylase) and the crtt mutant (defective in cross-linking during
critical role that chitin plays in the anchoring of the β-glucan network. However, EB-treated cells had no resemblance to the deletion mutants of the major (Fks1) and minor (Fks2) subunits of GS (Figure 6). This is consistent with previous observations (Ohnuki et al., 2010; sporulation) were different from NZ-treated cells (Rodríguez-Peña et al., 2000; Gómez-Esquer et al., 2004; Cabib et al., 2007). NZ-treated cells were also morphologically similar to mutants lacking CHS5 (Figure 6), which is involved in the trafficking of Chs3 and Utr2 (Rodríguez-Peña et al., 2002). These results highlight the critical role that chitin plays in the anchoring of the β-glucan network.

However, EB-treated cells had no resemblance to the deletion mutants of the major (Fks1) and minor (Fks2) subunits of GS (Figure 6). This is consistent with previous observations (Ohnuki et al., 2010; 2013; Rodríguez-Peña et al., 2002). These results highlight the critical role that chitin plays in the anchoring of the β-glucan network.

### FIGURE 2: Summary of the morphological changes induced by cell wall–affecting drugs. Morphological changes induced by the drugs were analyzed using two-step PCA to identify representative parameters for each drug (see Materials and Methods). Representative parameters for each drug (underlined) and those identified for another drug but significantly affected by the indicated drugs are shown with illustrations of the cells (Jonckheere-Terpstra test; <1 false positive was detected by chance at $p = 0.0013$, $0.0052$, and $0.0033$ for EB, TM, and NZ, respectively; Supplemental Table S3). Colored text indicates shared morphological features among drugs; red, green, blue, and brown represent features shared by EB–TM–NZ, EB–TM, EB–NZ, and TM–NZ, respectively. Asterisks denote features shared by EB and $fks1-ts$ mutants; single, double, and triple asterisks indicate features shared by EB and class I and III, class II, and class II and III, respectively (Supplemental Table S5).

<table>
<thead>
<tr>
<th>Phase</th>
<th>EB</th>
<th>TM</th>
<th>NZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1 phase</td>
<td>- Large cell **</td>
<td>- Large cell</td>
<td>- Delocalized actin</td>
</tr>
<tr>
<td></td>
<td>- Large nucleus with contour deviated from ellipse ***</td>
<td>- High variance in cell size</td>
<td>- Wide neck</td>
</tr>
<tr>
<td></td>
<td>- Delocalized actin ***</td>
<td>- Wide neck</td>
<td>- Large nucleus</td>
</tr>
<tr>
<td></td>
<td>- Decrease in number of actin patches</td>
<td>- Large nucleus with contour deviated from ellipse ***</td>
<td>- Small bud</td>
</tr>
<tr>
<td>S/G2 phase</td>
<td>- Large cell **</td>
<td>- Large cell</td>
<td>- Large cell **</td>
</tr>
<tr>
<td></td>
<td>- High variance in cell size</td>
<td>- Wide neck</td>
<td>- High variance in cell size</td>
</tr>
<tr>
<td></td>
<td>- Wide neck</td>
<td>- Large nucleus with contour deviated from ellipse ***</td>
<td>- Small bud</td>
</tr>
<tr>
<td></td>
<td>- Low proportion of cells with one nucleus in mother ***</td>
<td>- Round bud</td>
<td>- Round bud</td>
</tr>
<tr>
<td>M phase</td>
<td>- Large cell **</td>
<td>- Large cell</td>
<td>- High variance in neck width</td>
</tr>
<tr>
<td></td>
<td>- High variance in cell size</td>
<td>- Wide neck</td>
<td>- Round bud</td>
</tr>
</tbody>
</table>

*Actin region, Cell region, Cell wall, Nucleus*
EB affects both class II and III domains
Recent topological analysis revealed that EB-resistance mutations accumulated as affected clusters of residues called hot spots at the extracellular surface of Fks1 (Johnson and Edlind, 2012). Hot spots 1–3 are located at amino acid residues of 635–649, 1354–1361, and 690–700, respectively, of Fks1 (Supplemental Table S6). Because these hot spots are considered to be the sites for direct interaction with EB, it is significant that class II and III mutations affected residues near these hot spots in the primary structure of Fks1p (Figure 7A and Supplemental Table S6). To determine whether EB inhibited the function of both class II and class III mutants, we examined the EB sensitivity of each of GS mutants. Both class II (fks1-1163) and class III (fks1-1154) mutants failed to grow in the presence of 0.5 μg/ml EB, indicating an EB-sensitive phenotype (Figure 9). In contrast, wild-type and class I mutants (fks1-1082) were capable of growth in the presence of 0.5 μg/ml EB. These results suggested that EB affected the functions of the regions of Fks1 that are altered by the class II and class III mutations.

We next determined whether the fks1 mutants with both class II and III defects were lethal. For this purpose, we constructed strains harboring single-domain (fks1-1163 and fks1-1154) and double-domain (fks1-11631154) mutations after a galactose-inducible FKS1 gene was introduced on a plasmid. We found that the double-domain mutants failed to grow even at 25°C, suggesting that class II and III domains had synergistic effects on the function of Fks1 (Supplemental Figure S7). Thus EB affected two related and important functions of Fks1: 1,3-β-glucan synthesis and cell polarity.

DISCUSSION
We used three drugs (EB, TM, and NZ) that cause distinct types of cell wall damage by inhibiting known targets to characterize the morphological changes induced by inhibiting the biosynthesis of the three major cell wall components, 1,3-β-glucan, mannoproteins, and chitin, in S. cerevisiae. Treatment with the three drugs induced several common morphological effects, including increased neck width and morphological variation. However, they also exhibited different effects on cell morphology, indicative of the distinct roles played by the cell wall components in cell morphogenesis. Results of chemical–genetic approaches using TM and NZ were consistent with the classical genetic approach, demonstrating that N-linked glycosylation and glucan/chitin cross-linking were important for morphogenesis. Moreover, EB had pleiotropic effects on cell morphology and affected multiple functions of Fks1, including maintenance of cell polarity and 1,3-β-glucan synthesis.

N-glycosylation pathway and cell morphogenesis
Statistical analysis revealed that the TM treatment induced several morphological features. Eight representative parameters were affected in a dose-dependent manner after treatment with TM.
the TM treatment showed significant similarity to individual deletions of the genes encoding mannosyltransferase in the Golgi, as well as \textit{cax4}, \textit{die2}, and \textit{ost6}, which mediate N-glycosylation in the ER. TM-treated cells were similar to an \textit{och1} mutant (a mutant of cis-Golgi \(\alpha\)-1,6-mannosyltransferase), deletion mutants of Golgi \(\alpha\)-1,6-mannosyltransferase and the M-pol II complex (\textit{mnn10},

(Supplemental Table S2b). For example, mother and daughter cells enlarged, nuclear size increased in unbudded cells, and the neck width increased. The increase in cell size was reported previously (Arnold and Tanner, 1982).

TM blocks the initial step of N-glycosylation by inhibiting Alg7 in the ER (Barnes et al., 1984). The morphological profile induced by the TM treatment showed significant similarity to individual deletions of the genes encoding mannosyltransferase in the Golgi, as well as \textit{cax4}, \textit{die2}, and \textit{ost6}, which mediate N-glycosylation in the ER. TM-treated cells were similar to an \textit{och1} mutant (a mutant of cis-Golgi \(\alpha\)-1,6-mannosyltransferase), deletion mutants of Golgi \(\alpha\)-1,6-mannosyltransferase and the M-pol II complex (\textit{mnn10},

FIGURE 4: Marked morphological variation among drug-treated yeast populations. (A, D, G) Variance in the morphological parameters affected by the drugs (A, EB; D, TM; and G, NZ) was plotted in the highest to lowest order. Black and gray circles indicate parameters of higher and lower variance compared with the control (=1, dashed line), respectively. Red circles denote morphological parameters exemplified in B, E, and H. (B, E, H) Examples of morphological parameters with increased variance upon EB, TM, and NZ treatment. (C, F, I) Distributions of morphological parameters exemplified in B, E, and H visualized using a box plot with single-cell resolution. Gray and white boxes denote single-cell distribution with and without drug treatment, respectively.
anp1, and hoc1), and a mnn2 mutant (a mutant of α-1,2-mannosyltransferase), which are defective in the first, third, and fourth steps, respectively, of outer-chain elongation of N-linked oligosaccharides in the Golgi (Jigami, 2008). Mnn9 is also a component of M-pol II (A complex), but forms another mannosyltransferase complex known as M-pol I (V complex), which functions in the second step with Van1 (Hashimoto and Yoda, 1997; Jungmann and Munro, 1998; Jungmann et al., 1999). Given that the morphological phenotypes of mnn9 and van1 differ from that of TM-treated cells, M-pol I may play additional roles in cell morphogenesis.

Loss of mannosyltransferase activity reduces protein mannosylation (Lagunas et al., 1986). Mutants defective in early glycosylation reactions exhibit aberrant cell wall assembly (Orłowski et al., 2007). These results suggest that N-glycosylation is necessary for the activity or stability of the proteins responsible for cell wall assembly. Unexpectedly, we found that the effects of TM treatment were similar to the effects caused by the single-gene deletion of Ccw12 (Figure 6; r = 0.66), highlighting the role of this mannoprotein in cell wall function (Mrsa et al., 1999; Ragni et al., 2011).

**Chitin synthesis and cell morphogenesis**

NZ had no severe effects on S. cerevisiae growth, and therefore its effect on cell morphology was expectedly minor. We found that neck width and bud roundness increased, whereas the ratio of unbudded cells with localized actin decreased. The wide-neck phenotype was reported previously (Schmidt et al., 2003). Note that no changes in nuclear morphology were detected.

Chitin is a polymer of 1,4-β-linked GlcNAc, contributing only 1–2% of the dry weight of the cell wall (Lesage and Bussey, 2006), which serves as a scaffold for anchoring 1,3-β- and 1,6-β-glucans. Chitin occurs in three different and polydispersed forms in the wall. In addition to free chitin, some is bound to 1,3-β-glucan and is present predominantly in the neck region, whereas a lesser amount is found in lateral walls bound to 1,6-β-glucan (Cabib and Durán, 2005; Cabib, 2009). We found that NZ-treated cells were morphologically similar to utr2, which was defective in glucan/chitin cross-linking (Cabib et al., 2007; Cabib, 2009). In addition, chs5 and pfa4 mutants, but not chs3, chs6, or chs7, all of which contain reduced levels of chitin, also showed a significant correlation with the NZ treatment cells. Of interest, only chs5 and pfa4 have additional defects on the intracellular traffic of other proteins, including the mislocalization of Utr2 in the chs5 mutant (Rodríguez-Peña et al., 2002). These results highlight the critical role of the chitin–glucan linkage in morphogenesis, in clear agreement with a recent proposal (Cabib and Arroyo, 2013), but also uncover a redundant role of the different chitin synthases in forming the chitin–glucan network.

**EB affects multiple functions of Fks1**

Echinocandin-family drugs (e.g., EB and micafungin) noncompetitively inhibit incorporation of UDP-glucose into 1,3-β-glucan
FIGURE 6: Morphological profiling of the cell wall–affecting drugs. The drug-induced morphological profiles were compared with 4718 mutants of nonessential genes, as described previously (Ohnuki et al., 2010). The vertical axis indicates the similarity to each gene deletion mutant as a $-\log_{10} p$ value of a correlation coefficient ($t$ test). The horizontal dashed line shows the threshold of $p = 1.06 \times 10^{-5}$ corresponding to a one-sided $p = 0.05$ after Bonferroni correction. Red dots denote cell wall–associated mutants (Lesage and Bussey, 2006; Orlean, 2012), with morphological profiles similar to those of drug-treated cells. Right, representative photographs of wild-type cells after drug treatment and representative deletion mutants ($fks1$, $mnn10$, and $utr2$). $R$ is the correlation coefficient between drug-treated and mutant cells. Bar, 5 μm.

FIGURE 7: Morphological phenotypes of EB-treated and $fks1$ cells. (A) Functional map of Fks1p (modified from Okada et al., 2010). The gray-hatched box denotes the plasma membrane. Red symbols on the black line indicate hot spots (the echinocandin resistance–conferring mutations). The amino acids mutated and the hot spots are listed in Supplemental Table S6. (B) PCA of the data sets of EB-treated and $fks1$ cells. Morphological data on EB-treated cells were mapped onto the 2D space obtained by PCA of the $fks1$-ts mutant (Okada et al., 2010). The grayscale within the circular symbols indicates the dose of EB used (from dilute to concentrated). PC1 and PC2 explained -60% of the variance.
FIGURE 8: Effect of EB on Spa2–GFP localization. (A) YOC5002 (spa2 [Spa2–GFP]) cells were incubated at 25°C in SD–U medium with EB (1 µg/ml) or DMSO (control solvent) until the early log phase. Cells were then harvested and observed without fixation. The arrowhead indicates the absence of Spa2–GFP localization in the bud. Bar, 5 μm. (B) Spa2–GFP localized cells were enumerated in three independent experiments. The mean of the triplicates is plotted. Error bars denote 1 standard deviation. Asterisk indicates significant difference (p < 0.05 by t test after Bonferroni correction).

FIGURE 9: EB sensitivity of the fks1-ts mutants. Cells were cultured in YPD medium until the log phase and diluted serially to 1 × 10^6, 1 × 10^5, 1 × 10^4, and 1 × 10^3 cells/ml. Suspensions of 5 μl were dropped on the plates contained EB or DMSO as a control solvent. Plates were incubated at 25°C for 3 d. The experiments were replicated at least twice, and representative results are shown. FKS1, fks1-1082, fks1-1154, and fks1-1163 indicate YOC4318, YOC4320, YOC4327, and YOC4328, respectively.

Preservation of the neck structure of the cell wall

We demonstrated that yeast cells had a broadened neck width after treatment with all cell wall–affecting drugs, suggesting that maintaining a narrow neck is a common function performed by cell wall components. Phenotypic analysis of several cell wall mutants supported this hypothesis. Mutation of genes involved in the outer-chain elongation of N-linked oligosaccharides in the Golgi (OCH1, MNN10, ANP1, and MNN2), CAX4 (N-glycosylation in the ER), and CCW12 (mannoprotein) resulted in significantly wider necks (data available at SCMD). Chs5, which is involved in the export of chitin synthase (Santos and Snyder, 1997; Santos et al., 1997), Kre6, which is required for 1,6-β-glucan biosynthesis (Roemer and Bussey, 1991), and 1,3-β-glucanosyltransferase (Gas1), which is required for cell wall assembly; Ram et al., 1998; Popolo and Vai, 1999), were also all necessary to maintain a narrow neck (data available at SCMD). Thus classical genetic and chemical–genetic approaches both resulted in common morphological phenotypes induced by the lesion of cell wall components.

All components of the yeast cell wall are localized at or near the bud neck. The filamentous components 1,3-β-glucan and 1,6-β-glucan are found on the interior of the cell wall around a constriction between the mother and daughter cells. Nonfilamentous component mannoproteins are also localized to this region on the exterior surface. In contrast, chitin is localized at the bud/birth scar and the primary septum. Several explanations of the wide-neck phenotypes caused by cell wall–affecting drugs are possible. Physical strength is presumably required to maintain the curvature structure of the neck. If the network structure of the cell wall is weakened, it may lead to morphological changes of the neck. Alternatively, neck morphology may be determined by many genes, among which those encoding enzymes responsible for synthesis of cell wall components may play important roles. Further studies are required to clarify the molecular mechanism underlying neck morphogenesis and demonstrate how it is related to cell wall functions.
Contribution of the cell wall to phenotypic robustness
We demonstrated that yeast cells were highly morphologically variable after perturbation of the cell wall components. We found significantly greater variations between the cell populations after treatment with cell wall–affecting drugs. Levy and Siegal (2008) identified yeast deletion mutants with highly variable phenotypes. In their study, the *anp1* mutant exhibited the second-highest variability in overall morphology and *mnn10* the 14th highest among all nonessential deletion mutants. Mutants (*och1*, *hoc1*, *mnn2*, *cax4*, and *ccw12*) defective in the mannoproteins, *gas1*, and *kre6* were also identified to be highly variable. Although the molecular mechanism is unclear, the cell wall structure likely provides robustness to the cell by protecting the intracellular functional network from environmental conditions.

Multivariate analysis to explore complex phenotypes
We used several multivariate approaches to investigate the complex phenotypes induced by cell wall–affecting drugs. To identify the morphological features after obtaining high-dimensional morphology data, we performed two-step PCA (Ohnuki *et al.*, 2012). This approach allowed us to demonstrate that all cell wall components had roles in the preservation of the neck structure and phenotypic robustness. To predict the gene deletion mutant whose morphological profile would be similar to that of the drug-treated cells, we used a high-content, image-based profiling method (Ohnuki *et al.*, 2010), which validated our analysis and indicated a similar function of chitin synthesis for chitin transglycosylase in morphogenesis. A combination of genetic and statistical analyses facilitated examination of the complex effects of cell wall–affecting drugs. Using these approaches, we determined the mode of action of EB using temperature-sensitive *fks1* mutants, which showed specific loss of the individual functions of Fks1.

Cell wall biosynthesis is a tightly coordinated dynamic biological process. Our results suggest mechanistic roles of the cell wall components in cell morphogenesis and increase our understanding of novel functions of the cell wall and the pharmacology of antifungal drugs. A similar approach could be used to investigate the functions of other cellular components in cell morphology.

MATERIALS AND METHODS

Strains and plasmids
The yeast strains and plasmids used in this study are listed in Supplemental Tables S7 and S8 and are deposited with the National BioResource Project Japan, Yeast Genetic Resource Center (Osaka, Japan). The *fks1* mutants were described as constructed previously (Okada *et al.*, 2010). Y02458 (as BY4741 his3::KanMX) was used as the wild-type strain. Standard procedures were used for all DNA manipulations and *Escherichia coli* transformations (Sambrook *et al.*, 1989).

Media and reagents
Yeast-rich medium (YPD) contained 1% Bacto yeast extract (BD Biosciences, San Jose, CA), 2% Bacto peptone (BD Biosciences), and 2% glucose. Yeast synthetic medium (SD or SGS) contained 0.66% Bacto yeast nitrogen base lacking amino acids (BD Biosciences), 2% glucose (SD) or 2% galactose, plus 0.2% sucrose (SGS), and was supplemented with the appropriate nutrients. Luria–Bertani medium for *E. coli* contained 1% Bacto tryptone (BD Biosciences), 0.5% Bacto yeast extract, and 1% NaCl. Stock solutions of 2 mg/ml EB (a gift from O. Kondo, Chugai Pharmaceutical, Tokyo, Japan) or 10 mg/ml TM (Sigma-Aldrich, St. Louis, MO) were prepared in dimethyl sulfoxide (DMSO; Wako Pure Chemical Industries, Osaka, Japan). Stocks of 10 mM NZ (Sigma-Aldrich) and 10 mg/ml micafungin (Astellas Pharma, Tokyo, Japan) were prepared in distilled water.

Quantification of the effects of drug treatment on cell morphology
Wild-type yeast strains were cultured at 25°C in YPD until the early log phase (~16 h) with 0, 1, 2, 3, or 4 μg/ml EB; 0, 20, 40, 60, 80, or 100 ng/ml TM; or 0, 10, 15, 20, 25, or 30 ng/ml micafungin. Strains treated with NZ (0, 80, 160, 240, 320, or 400 μM) were cultured in SD. The concentrations of cell wall–affecting drugs were determined based on the growth inhibition rates (~10%, excluding NZ, which did not significantly inhibit the growth of *S. cerevisiae*). Cell fixation, staining, and observation were performed as described previously (Ohnuki *et al.*, 2012). Images were analyzed using the image processing software CalMorph (version 1.2), which extracted a total of 501 morphological quantitative values from at least 200 individual cells in each experiment. Images were processed using Photoshop CS2 (Adobe Systems, San Jose, CA) for illustrative purposes.

Statistical analysis
Morphological profiling of the drugs using the Jonckheere–Terpstra test was performed to assess the morphological similarity between the cells treated with the cell wall–affecting drugs and nonessential deletion mutants (Jonckheere, 1954; Ohnuki *et al.*, 2010). Other statistical analyses, including PCA, were performed using R, version 2.14.0 (www.r-project.org/).

Two-step PCA
Before applying PCA to morphological parameters, we transformed five replicated parameters to rank-sum values to unify the distribution of each parameter, as described previously (Ohnuki *et al.*, 2012). In the first PCA, morphological data on cells treated with the drugs were subjected to PCA (Supplemental Figure S1). The dose-dependent parameters were correlated with the first principal component (PC1) significantly (Supplemental Table S1, a–c) and had high absolute loading values to PC1. Of the 501 parameters, significant PC loadings in PC1 were observed for 265, 168, and eight parameters in the EB, TM, and NZ data sets, respectively (false discovery rate = 0.1 by t test). In the second PCA, data obtained from 122 replicated experiments of wild-type cells (null-distributed data) in the correlated parameters were subjected to PCA after Box–Cox power transformation. The parameter-correlating PCs in the second PCA, explaining 60% of the variance, had significant loadings (>0.5) at p < 0.0001 based on the t test after Bonferroni correction (Supplemental Figure S2, A and B). Several independent PCs, named in alphabetical order (e.g., PC1, PC2, and PC3 were named PC1a, PC1b, and PC1c, respectively), were extracted for each drug (Supplemental Table S2, a–c). One or two dose-dependent parameters of the various morphological criteria were selected as representative parameters after taking the absolute loading values to each PC (>0.5) and the meaning of the parameters (colored in yellow in Supplemental Table S2, a–c) into account.

Estimation of the variation in cell morphology
Parameters showing notable dose-dependent drug effects were detected using the Jonckheere–Terpstra test (p < 0.05). Of the detected parameters (354 parameters in EB, 241 in TM, and 87 in NZ), the “mean” parameters (197, 127, and 37 parameters, respectively)
representing the population average were analyzed further. The data on cells treated with a high concentration of drugs (4 μg/ml EB, 100 ng/ml TM, and 400 μM NZ; n = 5) were centered by subtracting the mean and scaled by dividing by the standard deviation of the control cells without drug treatment (n = 5) and then used to assess the effects of the drugs on cell morphology.

**Extraction of similar/dissimilar effects of drug treatments**

After PCA on the morphological data for the drug-treated cells, the loadings of 501 traits for PC1 were plotted on the 2D space of two or three arbitrary drugs. Because PC1 scores of all three drugs increased in a dose-dependent manner, we assumed that the traits correlating with PC1 in the same direction (a positive or negative correlation) between the drugs reflected similar effects. Conversely, traits in different directions reflected dissimilar effects. For pairwise comparisons among the three drugs (EB–TM, EB–NZ, and TM–NZ), we defined similar parameters (369, 289, and 293 traits) and dissimilar parameters (132, 212, and 208 traits, respectively) from 501 traits based on the loadings. To identify the primary effects of the drugs on each set of similar/dissimilar parameters, we applied PCA independently (Supplemental Figure S3) and visualized the distribution of PC1 scores.

**Spa2 localization**

To assess Spa2 localization, we constructed a plasmid expressing a Spa2–GFP fusion protein with GFP conjugated immediately after the stop codon. A DNA fragment of the SPA2 open reading frame, with its 0.5-kb-upstream region, was amplified from the S. cerevisiae genome by PCR using primers that generated a Smal restriction site at each end. The PCR product was cloned into a low-copy vector and transformed into S. cerevisiae. The SPA2 expression plasmid was confirmed by sequencing. After transformation, the yeast were grown in SD–uracil medium and cells from log phase were filtered on PDMS with a pore size of 1 μm before staining with Hoechst 33342 and analyzed by fluorescence microscopy.

**ACKNOWLEDGMENTS**

We thank Osamu Kondo for providing EB, Satoru Nomaguchi for initiating analysis of the morphology data, and members of the Laboratory of Signal Transduction for helpful discussions. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (21301027 and 24370002 to Y.O.), a grant from the Comisión Interministerial de Ciencia y Tecnología, Spain (BFU2010-18632 to C.R.), and a Public Health Service grant from the National Institute of Allergy and Infectious Diseases (AI-47837 to J.B.K.). H.O. and S.O. were Research Fellows of the Japan Society for the Promotion of Science.

**REFERENCES**


Cabib E (2009). Two novel techniques for determination of polysaccharide cross-links show that Chr1p and Chr2p attach chitin to both beta(1-6)- and beta(1-3)-glucan in the Saccharomyces cerevisiae cell wall. Mol Microbiol 63, 921–935.


lees and antifungal drugs. Drug Resist Updat 10, 121–130.”

